Movement Alert｜SBP GROUP Rises 3.15% in Regular Trading, Citigroup Retains Buy Rating on STADA Collaboration

Market Focus10-06 09:43

On October 6, SBP GROUP rose 3.15% in regular trading, extending its recent upward trend amid positive market sentiment.

The increase follows Citigroup maintaining a buy rating and setting a target price of HKD 10.80, driven by optimism around its strategic partnership with STADA for pembrolizumab biosimilar TQB3570. Under this agreement finalized in late September, SBP GROUP secured upfront payments and could receive up to €53 million in milestone payments plus double-digit profit sharing, with cumulative potential deal value reaching approximately $3.4 billion this year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment